ABOUT PHYLLANTHUS
Why Phyllanthus?
-
- Because
limitation of lamivudine
- Because
limitation of interferon
- The role of Phyllanthus in the management of hepatitis
B infection
1. Because
current therapy is not sufficient - the unmet clinical needs
More than 400 million people worldwide
are chronically infected by the hepatitis B virus (HBV). 82% of
the world's 530,000 cases of liver cancer per year are caused by
virus hepatitis infection, with 316,000 cases associated with hepatitis
B. HBV infection is one of the commonest infections in the world.
According to World Health Organization (WHO), a third of the world's
population (2 billion people) has been infected with HBV and about
5% are chronically infected. Chronic hepatitis B can causes cirrhosis
and liver cancer. Despite the availability of antiviral therapy,
there are more than a quarter of people with chronic hepatitis B
will die of liver disease and more than 1 million people with infection
are estimated to die every year.
Natural course of primary hepatitis B infection
acquired during childhood or adulthood
Phyllanthus contains more than 50 compounds, which
explains its broad range of activity from liver protection effect
to antiviral activity, blood sugar reducing effect to cholesterol
lowering effect. It is believed that tannins, might account for
the antiviral effect and the flavonoids, is responsible for the
beneficial effect against liver toxicity. It is the combined activity
that might be responsible for its polyvalent therapeutic actions,
which are essential for treating disorders of multifactorial origin.
One of the active constituents is a phenolic compound
known as corilagin. It has been proven as a potent anti-hepatitis
B viral agent. Although it is too early to understand how to unravel
the cellular and molecular mechanisms that underlie the therapeutic
actions of Phyllanthus extract, these are some possible modes of
action of how Phyllanthus exerts its therapeutic actions:
- Inactivation of HBsAg
- Inhibition of RNA polymerase and RT
- Hepato-protective, and
- Immuno-modulation activity1
2. Because
limitation of lamivudine
- In 30% to 50% of patients taking this drug, the hepatitis B
virus eventually develops viral resistance (YMDD mutation), resulting
in a lack of success over a treatment period of 1 to 2 years.
- The appropriate length of treatment with these antiviral agents
is unclear. Most hepatologists prescribe them indefinitely.
3. Because
limitation of interferon
- Interferon may not be effective in lowering the hepatitis B
viral load.
- Interferon may be relapses after treatment is completed.
4. The
role of Phyllanthus in the management of hepatitis B infection
- It is a potent liver protection agent
- Guangzhou study has reported that Phyllanthus offers the following
advantages and benefits:
- When Phyllanthus was used alone for hepatitis B patients
with 4 capsules, 3 times a day, it offered ...
- When Phyllanthus was used in combination with lamivudine,
it showed that:
- HBeAg
- DNA
- Mutation - resistant strain reduced.
- Ignacio S, Ferriera J, Almeida M, et al. Nitric oxide production
by murine peritoneal macrophages in vitro and in vivo treated
with Phyllanthus extracts. J. Ethnopharmacol. 2001. 74: 181-187.
|